Most significantly, we showed the efficacy of these BAFF‐R CAR T cells against three CLL cell lines, CD19‐knockout (KO) CLL cells, and primary tumor cells from CLL patients. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.